Pliant Therapeutics, Inc. (PLRX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shareholder activism is viewed as a potential external pressure on Pliant Therapeutics, Inc., as campaigns by activist investors could impose substantial advisory, legal and communication costs while diverting management and board attention away from core clinical and commercialization priorities. Such activism may also disrupt relationships with employees and third-party partners, complicate talent retention and strategic execution, and could trigger proxy contests or litigation, including challenges related to any shareholder rights plans, thereby adding volatility and downside pressure to the company’s stock price.
Overall, Wall Street has a Moderate Buy consensus rating on PLRX stock based on 1 Buy and 2 Holds.
To learn more about Pliant Therapeutics, Inc.’s risk factors, click here.